Despite optimal pharmacotherapy and cognitive-behavioral treatments, a proportion of patients with obsessive-compulsive disorder (OCD) remain refractory to treatment. Neurosurgical ablative or nondestructive stimulation procedures to treat these refractory patients have been investigated. However, despite the potential benefits of these surgical procedures, patients show significant surgery-related complications. This preliminary study investigated the use of bilateral thermal capsulotomy for patients with treatment-refractory OCD using magnetic resonance-guided focused ultrasound (MRgFUS) as a novel, minimally invasive, noncranium-opening surgical technique. Between February and May 2013, four patients with medically refractory OCD were treated with MRgFUS to ablate the anterior limb of the internal capsule. Patients underwent comprehensive neuropsychological evaluations and imaging at baseline, 1 week, 1 month and 6 months following treatment. Outcomes were measured with the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), the Hamilton Rating Scale for Depression (HAM-D) and the Hamilton Rating Scale for Anxiety (HAM-A), and treatment-related adverse events were evaluated. The results showed gradual improvements in Y-BOCS scores (a mean improvement of 33%) over the 6-month follow-up period, and all patients showed almost immediate and sustained improvements in depression (a mean reduction of 61.1%) and anxiety (a mean reduction of 69.4%). No patients demonstrated any side effects (physical or neuropsychological) in relation to the procedure. In addition, there were no significant differences found in the comprehensive neuropsychological test scores between the baseline and 6-month time points. This study demonstrates that bilateral thermal capsulotomy with MRgFUS can be used without inducing side effects to treat patients with medically refractory OCD. If larger trials validate the safety, effectiveness and long-term durability of this new approach, this procedure could considerably change the clinical management of treatment-refractory OCD.
INTRODUCTION
Obsessive-compulsive disorder (OCD) is a common psychiatric disorder, and its lifetime prevalence in the United States is 1.6%. 1 Although a large proportion of patients improve with treatment, some patients demonstrate symptoms that are both refractory to medical therapy and severely debilitating. Neurosurgical treatment options that are either destructive or nondestructive and invasive or noninvasive have been used in these refractory cases. [2] [3] [4] [5] In early work at the Karolinska Institute, Mindus and colleagues 6 demonstrated the potential utility of radiofrequency thermal capsulotomy to treat patients with severe OCD. This surgical procedure, which is both destructive and invasive, has been established as an effective procedure. 7, 8 However, because this procedure is invasive, it requires penetration of the probe through the cerebral cortex to the lesion target location, which can be associated with surgical complications. In addition, it is only possible to monitor the temperature of the lesioning electrode during the lesioning procedure. Thus, the size and location of the lesion are variable, which can lead to further complications. Compared with radiofrequency thermal capsulotomy, gamma capsulotomy is a fully noninvasive procedure used to destroy a target. However, gamma capsulotomy has potentially unpredictable radiation-associated adverse effects, which could be either transient or permanent. 9 Furthermore, the production of the lesion cannot be monitored during or immediately following the procedure. Thus, both radiofrequency thermal or gamma capsulotomies not only create irreversible lesions, but they also cannot be adjusted to correct the size and/or location of the lesion during the procedure.
Deep brain stimulation (DBS) is an alternative to lesioning procedures that has been widely used for movement disorders such as Parkinson's disease, essential tremor and dystonia because of its unique characteristics of adjustability and reversibility. There are various DBS targets for OCD, including the nucleus accumbens, the nucleus caudalis, the subthalamic nucleus, the ventral internal capsule/ventral striatum and the anterior limb of the internal capsule (ALIC). 5 Although DBS shows the specific benefits of reversibility and adjustability, lesioning procedures have their own benefits, such as the avoidance of general anesthesia, programming burdens, additional operations for battery changes and implantation-related complications, including lead fracture, migration and infection, among others. 10, 11 Recently, thermal lesioning with magnetic resonance-guided focused ultrasound (MRgFUS) was introduced as a novel, minimally invasive, non-cranium-opening surgical technique and was shown to be effective without inducing serious side effects. 12, 13 The primary benefit of MRgFUS is the closed-loop monitoring of the lesion in real time, thus confirming the size and location of the lesion during every stage of the lesioning procedure. Furthermore, MRgFUS enables monitoring of the patient's condition, as well as identification of potential side effects, throughout the procedure.
In the present study, we demonstrate, for the first time, the preliminary effects of bilateral thermal capsulotomy with MRgFUS to treat patients with treatment-refractory OCD.
MATERIALS AND METHODS Patients
Between February and May 2013, four OCD patients were treated with MRgFUS after they provided informed consent. Before beginning the study, we received full approval for clinical feasibility studies for patients with OCD (protocol #OCD001) from the Institutional Review Board of the Human Research Protection Center of Severance Hospital (Seoul, Korea) and the Korean Food and Drug Administration.
All psychiatric interviews for the diagnosis and assessment of symptoms or psychosocial functions were conducted by two experienced psychiatrists (SJK and DR). The inclusion criteria were as follows: (1) a primary OCD diagnosis according to the Structured Clinical Interview of the Diagnostic and Statistical Manual of Mental Disorders; (2) at least a 3-year history of OCD symptoms with psychosocial dysfunction (determined by a Global Assessment of Functioning Scale, score ⩽ 50); (3) a minimum score of 28 on the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS); and (4) treatmentrefractory status, that is, non-responsive to pharmacological treatment (more than two types of serotonin reuptake inhibitors at the maximum tolerated dose for more than 12 weeks) and cognitive-behavioral therapy (a minimum of 20 sessions of primarily therapist-guided Exposure and Response Prevention (ERP)). Full inclusion and exclusion criteria can be found at the website http://clinicaltrials.gov/ct2/show/NCT01986296? term = focused+ultrasound+and+OCD&rank = 1.
However, we initially recruited OCD subjects with a greater number of refractory characteristics than the inclusion criteria; all patients exceeded the number and duration of treatments required to satisfy the entry criteria. All patients failed to be responsive to more than three serotonin reuptake inhibitors, including clomipramine, and more than one antipsychotic drug augmentation strategy (⩾1 serotonin reuptake inhibitor + ⩾ 1 antipsychotic) and had at least a 5-year history of OCD symptoms with psychosocial impairment. OCD subjects with current or previous psychotic disorders, bipolar disorder or significant cognitive impairments (based on a Mini Mental Status Examination, score ⩽ 24) were excluded from the study.
Previous medication was kept stable for at least 30 days before MRgFUS, and the dose was maintained until the final follow-up visit. After 1 week following MRgFUS, patients were encouraged to utilize the cognitive and behavioral skills they had previously learned during ERP. All patients visited the psychiatric clinic every 2-4 weeks after the first week following MRgFUS. During each visit, the psychiatrist (SJK or DR) educated and reminded the patient about ERP techniques and verified the patient's efforts to perform ERP. The patient demographics and clinical characteristics are presented in Table 1 .
Procedures
MRgFUS was performed in a 3-T MR imaging (MRI) system (GE Medical System, Milwaukee, WI, USA) using the ExAblate 4000 (InSightec, Haifa, Israel), which features a 30-cm diameter, hemispherical, 1024 element phased-array transducer operating at 650 kHz and held by a mechanical positioner. The patient's scalp was shaved completely and the head was immobilized in a Cosman-Roberts-Wells stereotactic frame (Integra, Plainsboro, NJ, USA) following a local anesthesia injection. After entering the MRI room, the stereotactic frame was fixed to the table, which was part of the ExAblate 4000 device. A presonication MRI was performed, and the images were fused with computed tomography and other MR sequences to determine target coordinates. We targeted the bilateral ALIC (7 mm anterior to the anterior margin of the anterior commissure at the same AC-PC plane, extending 2-3 mm along the capsule from a coronal view). Several subthreshold heatings with low-power sonications of 10 s duration were applied to induce peak temperatures of 40-42°C. This procedure allowed us to visualize the exact position and size of the thermal spot and the overall safety profile of the applied sonication parameters. High-power sonications were then applied in an iterative process guided by MRI and MR thermometry, with stepwise increases in acoustic power and energy to achieve a peak temperature in the target region of 51-56°C for more than 3 s. The goal was to create a 10-mm elliptical lesion by adjusting the target center. To determine whether there were any adverse effects induced by the MRgFUS capsulotomy procedure, the patient, fixed in the MR couch, was physically and neurologically evaluated by a neurosurgeon, who assessed the presence of lateralizing symptoms or signs, and by a psychiatrist, who interviewed the patient to determine whether there were mood changes or decreases in cognition before and after every sonication. The number of sonications for the entire lesioning procedure ranged from 23 to 36, with 10-31 s durations, and the overall procedure lasted 5-7 h. All patients were fully awake and responsive during the entire procedure, after which they were monitored for~24 h as inpatients.
Follow-up examinations and clinical evaluations
T1-weighted imaging with and without contrast enhancement, T2-weighted imaging, diffusion-weighted imaging and fluid-attenuated inversion recovery sequences were conducted to detect the lesion following sonication. Axial, sagittal and coronal T1-and T2-weighted fast spin echo All four patients' Y-BOCS scores were higher than 34 with a duration of more than 10 years. These patients were refractory to medication and CBT.
images were obtained before and after the MRgFUS and compared with changes in MRI scans immediately, 1 week, 1 month and 6 months following the MRgFUS. The Y-BOCS, the Hamilton Rating Scale for Depression (HAM-D) and the Hamilton Rating Scale for Anxiety (HAM-A) were assessed by the psychiatrists at baseline, 1 week, 1 month, 3 months and 6 months following the MRgFUS. Neuropsychological tests, including the Wechsler Adult Intelligence Scale-Korean version (K-WAIS), the Memory Quotient (MQ) of the Rey-Kim Memory Test, the Controlled Oral Word Association Test (COWAT) and the Stroop test, were also assessed by the psychiatrists at baseline and at 6 months following the MRgFUS.
Potential adverse effects and any changes in the patient's neurological and physical states were determined and evaluated at every visit by a neurosurgeon and a psychiatrist. The study protocol for OCD001 is presented on the Clinical Trials website (http://www.clinicaltrials.gov/ct2/ show/NCT01986296?term = OCD001&rank = 2).
RESULTS
Clinical course of obsessive-compulsive, depression and anxiety symptoms Following thermal capsulotomy with MRgFUS, all patients continued their medications without modifications. The Y-BOCS scores at baseline ranged from 34 to 38. The mean baseline Y-BOCS score of 35.3 ± 1.9 decreased over the course of the follow-up testing to 23.5 ± 4.9 at the 6-month time point, with an improvement rate of 33 ± 11% at the end of the 6 months. Two of the four patients met the criteria for a full response (a greater than 35% improvement in the Y-BOCS score) during the follow-up period, but all four patients showed, at minimum, a gradual decline in their Y-BOCS score.
The mean HAM-A score at baseline was 27 ± 7.4, which decreased to 8.3 ± 6 at the 6-month time point (a 69.4% improvement). The improvement rates were 62, 66.7, 66.7 and 69.4% at 1 week, 1 month, 3 months and 6 months following MRgFUS, respectively. All four patients showed marked improvements on their first visit and 1 week following MRgFUS, and this improvement continued throughout the follow-up period.
The mean HAM-D score at baseline was 22.5 ± 4.2, which improved to 8.8 ± 3.3 at the 6-month time point (a 61.1% improvement). The improvement rates were 52.2, 64.4, 55.6 and 61.1% at 1 week, 1 month, 3 months and 6 months, respectively.
The HAM-D scores showed early improvements that were similar to the HAM-A changes.
The scores and the clinical course are described in Table 2 and Figure 1 .
The full battery of neuropsychological tests before and after MRgFUS The full battery of neuropsychological tests described above was conducted at baseline and at 6 months following MRgFUS. Compared with baseline, there were no significant score changes following the MRgFUS procedure. The mean scores (± s.e.m.) at baseline and after 6 months, respectively, were as follows: K-WAIS, 97.8 ±21.7 and 101.0 ± 23.8; MQ, 99.8 ± 4.9 and 106.0 ± 10.9; semantic portion of the COWAT, 19.3 ± 6.8 and 20.3 ± 3.3; phonemic portion of the COWAT, 38.0 ± 16.8 and 37.0 ± 16.3; and the Stroop response, 0.874 ± 0.4 numbers per second and 0.919 ± 0.3 numbers per second. The K-WAIS and Stroop responses increased in three out of four patients, but these differences were not statistically significant (Table 3) .
Imaging findings following MRgFUS The patterns of MRI changes were similar in all four OCD patients. Thermal capsulotomy was performed bilaterally, with the lesioning of the right hemisphere performed first, and a signal change appeared in T2-weighted images during sonication of the left hemisphere. Lesions in the ALIC were invisible in T2-weighted or diffusion-weighted images during or immediately following the ipsilateral sonication. The minimal enhancement of the lesion immediately following sonication was presumably due to the opening of the blood-brain barrier. One week following sonication, the lesions became more distinct, and the enhancement of the lesions disappeared. Mild perilesional edema was noted at 1 week; however, this edema had completely disappeared in the 1-month follow-up images. Six months following sonication, the lesions were slightly reduced in size and appeared small with a hyperintense signal in T2-weighted images (Figure 2 ).
Complications and other clinical features
During sonication at temperatures greater than 50°C, all patients felt several short, periodic headaches, which were mild enough 1  3 8  3 6  3 5  3 2  2 9  2 4  2  3 4  3 2  2 7  1 8  1 8  4 7  3  3 5  3 1  3 2  2 8  2 that analgesics were not required. In addition, longer periods in the MR machine led to increased vestibular symptom complaints, such as nausea, vomiting or dizziness, in three patients (no. 1, 3 and 4), which lasted until the end of the procedure. We controlled nausea with an intravenous antiemetic drug injection, which did not extend the procedure length, and all three patients received the injection once. No demonstrable physical, neurological or psychological persistent complications, such as confusion, personality changes, hypomania, apathy, disinhibition or executive dysfunction, among others, occurred in these patients; these complications typically occur following radiofrequency thermal capsulotomy, gamma capsulotomy or DBS.
The following changes in body weight were recorded for each patient: patient 1: 62-63 kg; patient 2: 65-74 kg; patient 3: 78-76 kg; and patient 4: stable at 45 kg. In addition, during the 6 months following bilateral thermal capsulotomy with MRgFUS, there were no additional procedure-related persistent complications.
DISCUSSION
Although pharmacological and cognitive-behavioral therapies are the first line of treatment modalities traditionally used for the management of OCD, a proportion of patients are refractory to these conventional treatments. 14, 15 These treatment-refractory patients are candidates for novel neurosurgical interventions, which have not been, to date, conducted with controlled trials. In early work at the Karolinska Institute, Mindus and colleagues 6 demonstrated the potential utility of radiofrequency thermal capsulotomy in patients with severe OCD. This surgery, which is both destructive and invasive, has been established as an effective procedure. However, because it is invasive, radiofrequency thermal capsulotomy could, inevitably, be associated with surgical complications. In addition, the size and location of the lesions are variable, which could induce further complications. Liu et al. 8 reported the following complications among 35 bilateral capsulotomy cases: 1 case of an intracerebral hematoma (3%), which required additional ventricular drainage; 2 cases of personality changes (5.7%); 3 cases of urinary incontinence and acute confusion (8.6%), which disappeared within 3-5 days; 9 cases of postoperative mild cognitive deficits and transient dementia (28.4%), each of which recovered within 3-10 days; and 1 case of weight loss. Although no additional serious complications were noted, such as severe adverse effects on personality or cognitive functioning, which agrees with the finding of Mindus et al. 16 from 19 patients, surgery-related complications should not be dismissed due to the unpredictable nature of the procedure. 7 For example, Ruck et al. found that numerous patients demonstrated variations in the size and ALIC location of the lesions following radiofrequency thermal capsulotomy. More importantly, the authors proposed the need for the creation of appropriate lesions in ALIC while avoiding multiple procedures and/or larger lesions to improve patient outcomes. 9 Compared with radiofrequency thermal capsulotomy, gamma capsulotomy is a fully noninvasive procedure used to destroy a target. More than 30 gamma capsulotomies have been reported in the literature, and at least 55% of these patients responded following the procedure. 17 Because it uses a high dose of radiation, which has not yet been properly defined, gamma capsulotomy could potentially cause unpredictable radiationassociated adverse effects that could be permanent. 9, 18 Apathy, memory problems, executive dysfunction, seizures and incontinence developed in two of the nine gamma capsulotomy patients in the Ruck et al. 9 series, due to radiation necrosis and brain edema, and these complications persisted during the followup period. A comparison of thermal and gamma capsulotomies in these cases indicates that repeated procedures with either thermocoagulation or radiation and high doses of radiation could lead to substantial adverse effects. A reduction in the maximum radiation dose, to 180 Gy by Lopes et al. 19 and to less than 150 Gy by Kondziolka et al., 2 led to mild (lasting for a few days) or nonexistent, respectively, side effects such as headaches, vertigo, weight changes and episodic nausea/vomiting. However, it remains unknown whether the cause of complications following gamma capsulotomy can be attributed to high dosage levels, large lesion volumes or variable target locations. In our MRgFUS capsulotomy cases, we did not observe and the patients did not complain of the aforementioned side effects. Changes in body weight of the patients were not significantly different in our study, although this measurement should be assessed for a longer follow-up period. Our patients did suffer from periodic headaches, which were mild and lasted less than 5 s, when the MR thermometry was above 50°C during the sonication. Vestibular symptoms were considered to be a result of magnetic fieldinduced vertigo, which is similar to motion sickness and caused by lengthy exposure times in a high-field (more than 2 T) MRI. 20 Furthermore, the production of the lesion cannot be monitored during or immediately following thermal or gamma capsulotomy procedures; thus, thermal or gamma capsulotomies cannot eliminate the risk of creating irreversible lesions. In addition, the lesion cannot be adjusted to correct the size and/or location during these procedures. 9, 18, 19, 21 In 2009, the US Food and Drug Administration approved DBS for OCD under the Humanitarian Device Exemption program. There are various DBS targets for OCD, including the nucleus accumbens, the nucleus caudalis, the subthalamic nucleus, the ventral internal capsule/ventral striatum and the ALIC. 5 DBS has the advantages of being both adjustable and reversible, but it also has complications related to the implantation device or procedure, such as lead fracture, migration and infection. DBS also requires specific programming and additional operations for battery changes, in addition to being a costly device. 10, 11, 22 Typically, both destructive and nondestructive procedures have been beneficial in~40-60% of medically refractory OCD patients. 6, 7, 9, 17, [23] [24] [25] [26] [27] Compared with conventional radiofrequency thermal capsulotomy or gamma capsulotomy, MRgFUS enabled us to create an exact and accurate lesion in the pre-planned target because of the real-time, closed-loop monitoring of the MR thermometry and sequential MR images. This procedure could allow physicians to examine and monitor patients during each stage of the sonication. Thus, thermal lesioning with an MRgFUS can create an exact and confined lesion in the ALIC without creating additional lesions in adjacent critical structures. 28, 29 Because of these advantages, we did not find any serious perilesional edemas in the final follow-up MR images; we observed only mild and transient perilesional edemas within the first month following the procedure, which did not produce any noticeable side effects for the patient and did not require medication to control. In this report, we administered a comprehensive battery of neurocognitive tests at baseline and 6 months following MRgFUS to determine potential adverse effects. The full battery of neurocognitive tests included verbal, movement and overall intelligence quotients via the K-WAIS, as well as categorical and word fluency abilities, known for detecting frontal lobe dysfunctions, via the COWAT. The scores of these tests did not differ significantly at 6 months following the MRgFUS compared with the scores at baseline. At the 6-month follow-up, clinical outcomes were in accordance with the imaging results, which showed a lesion only in the restricted and intended area.
Furthermore, our study demonstrates for the first time that effective bilateral thermal capsulotomy is feasible using MRgFUS outside of the thalamic targets seen in previous clinical trials assessing essential tremors and neuropathic pain. 12, 13 Our 6month follow-up imaging data confirm the beneficial effects of this surgical procedure. Obsessive-compulsive symptoms improved in all four patients over the 6-month follow-up period, with a mean improvement in Y-BOCS scores of 33 ± 11%. This pattern of improvement is similar to other treatment modalities, although the Y-BOCS score improvement reached 35% in only two of four patients. 7, 24, 27 Importantly, an almost immediate response following MRgFUS was noted in our study, and interestingly, both HAM-D and HAM-A scores improved significantly immediately following the procedure; these improvements were maintained throughout the 6-month follow-up period. More importantly, although the follow-up period was short, there were no significant score changes in the full battery of neuropsychological tests over this time period, and we did not observe any serious neurological side effects in the four patients with treatment-refractory OCD. Only one patient (no. 2) showed a weight gain (9 kg) over this short time period, and this gain should be followed for an additional length of time.
Temperature increases above 52°C for more than 3 s are required to create permanent lesions using MRgFUS. However, there could be failures and insufficient temperature rises, the cause of which is not completely known. Several factors have been suggested to cause a loss of focus during sonication, such as skull density, volume, shape and thickness, among others. 30 In addition, the target location, the angle of the ray to the skull and the distance from transducer to the skull could affect acoustic energy delivery. Furthermore, data collection and technical development are required to overcome the limitations of a transcranial MRgFUS and to clarify the indications related to skull properties.
Although our preliminary results indicate a meaningful advance in psychosurgery, we should not overlook the limitation that only a small subset of well-characterized, highly ill and refractory OCD patients could be considered as surgical candidates. 31, 32 
CONCLUSIONS
The bilateral thermal capsulotomy with MRgFUS used in this study for the treatment of patients with medically refractory OCD led to an improvement in Y-BOCS scores, along with marked improvements in HAM-A and HAM-D scores, without causing neuropsychological or neurological dysfunction within 6 months of follow-up testing. Although our study was conducted with a small number of patients, further collection of data and validation of these results could confirm MRgFUS as an additional, minimally invasive, non-cranium-opening treatment modality for treatmentrefractory OCD patients in the near future.
